(Sharecast News) - AIM-listed Craneware has said it expects its full-year results to be below market expectations due to the timing of the 340B drug pricing programme in the US and the deferral of several contracts.
Craneware, which provides financial software and solutions to the US healthcare market, now expects...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE